T1	Participants 219 267	patients with advanced epithelial ovarian cancer
T2	Participants 194 218	169 previously untreated
T3	Participants 462 477	Eleven patients
T4	Participants 570 651	153 patients evaluable for response, there were 47, or 30.7%, complete responders
